Sunday 18 October 2026
Export IKT’s income statement to Excel — free account
Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $260,500.00, up 111.1% from fiscal 2022. In the quarter to June 2026, EPS was flat and free cash flow fell 123.2%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
1.65
0.18
−9.84%
Follow IKT
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
— | — | 3 | 2 | 4 | 4 | — | — | — |
P/S ratio |
— | — | 30.78 | 111.13 | 8.63 | 81.92 | 105.66 | 105.66 | 105.66 |
Altman Z-Score |
— | — | (8.82) | (2.14) | 2.99 | 5.62 | — | — | — |
Altman Z″-Score (non-manufacturers) |
— | — | (16.20) | (0.04) | 11.26 | 1.92 | (2,760.23) | (18.10) | — |
P/FCF ratio |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
— | — | (2.33) | (3.86) | (6.54) | (60.44) | 1,075.34 | 1,075.34 | 1,075.34 |
Beneish M-Score |
— | — | — | (0.15) | (0.05) | — | — | — | — |
P/B ratio |
— | — | 0.73 | 0.65 | 0.70 | 5.85 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
— | — | 0.73 | 0.65 | 0.70 | 5.85 | 0.00 | 0.00 | 0.00 |
EV/Sales |
— | — | (20.10) | (75.51) | (4.51) | 61.93 | 105.65 | 105.65 | 105.65 |
EV/EBITDA |
— | — | 0.26 | 0.51 | 0.95 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | — | 0.29 | 0.54 | 0.98 | (38.30) | (155.88) | (155.88) | (155.88) |
EV/FCF |
— | — | 0.29 | 0.53 | 0.98 | (38.30) | (155.88) | (155.88) | (155.88) |
Quick Ratio |
21.54 | 26.13 | 3.85 | 6.25 | 10.08 | 3.12 | 0.00 | 0.24 | 0.11 |
Current Ratio |
21.70 | 26.37 | 4.13 | 6.60 | 10.47 | 3.13 | 0.01 | 0.35 | 0.11 |
Net Debt/EBITDA |
3.44 | 3.42 | 0.67 | 1.27 | 2.76 | 4.95 | 0.00 | 0.18 | (1.09) |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.32) |
Asset Turnover |
0.00 | 0.00 | 0.01 | 0.00 | 0.11 | 0.09 | 0.78 | 2.84 | 1.32 |
Operating CF/Net income |
0.58 | 0.70 | 0.95 | 0.96 | 0.97 | 0.40 | 0.06 | (0.33) | 0.29 |
Capex/Depreciation |
(0.22) | 0.00 | (0.08) | (36.31) | — | — | — | — | — |
Interest Coverage |
— | — | — | (243.34) | (742.02) | (95.87) | (229.76) | (70.04) | (26.22) |
| (36.05%) | (52.00%) | (118.88%) | (60.74%) | (61.35%) | (107.58%) | 217.27% | 194.01% | 39.31% | |
| (34.49%) | (48.66%) | (96.49%) | (53.57%) | (51.65%) | (38.43%) | (396.78%) | (151.24%) | (27.85%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(28.09%) | (29.04%) | (175.45%) | (86.33%) | (38.49%) | (28.31%) | 135.70% | 90.72% | 28.54% |
Average Days of Receivables |
— | — | 0.00 | 118.02 | 12.96 | 404.66 | 0.00 | 42.71 | 32.02 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 5,227.79% | 9,752.84% | 366.35% | 127.96% | 227.37% | 90.25% | 85.19% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 2,584.22% | 5,038.17% | 209.88% | 375.55% | 380.17% | 62.26% | 34.47% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 191.98% | 371.23% | 49.41% | 82.13% | 127.96% | 15.89% | 0.00% |
Graham Net Nets |
— | — | 1.33 | 1.49 | 1.43 | 0.17 | 0.00 | 0.00 | 0.00 |
Graham Number |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | — | (267.65%) | (131.05%) | (58.49%) | (5.08%) | (2.09%) | (2.09%) | (2.09%) |
Free Cash Flow Yield |
— | — | (225.75%) | (128.19%) | (53.40%) | (1.97%) | (0.64%) | (0.64%) | (0.64%) |
Revenue per Share |
0.00 | 0.00 | 0.04 | 0.03 | 1.02 | 0.51 | 0.82 | 3.02 | 0.20 |
Operating CF per Share |
(0.28) | (0.81) | (3.00) | (4.11) | (4.71) | (0.82) | (0.25) | 0.54 | (0.01) |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.06) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(0.28) | (0.81) | (3.00) | (4.17) | (4.71) | (0.82) | (0.25) | 0.54 | (0.01) |
Cash per Share |
1.82 | 4.11 | 2.20 | 5.46 | 13.42 | 10.19 | 0.01 | 0.28 | 0.00 |
Shareholders Equity per Share |
1.76 | 4.00 | 1.82 | 4.98 | 12.66 | 7.15 | (3.29) | (0.58) | (0.14) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.76 | 4.00 | 1.82 | 4.98 | 12.66 | 7.15 | (3.29) | (0.58) | (0.14) |
Free Cash Flow |
(27.80) | (19.15) | (18.10) | (17.59) | (14.30) | (1.13) | (0.34) | 0.72 | (0.13) |
Working Capital |
171.81 | 94.72 | 10.77 | 20.68 | 38.42 | 10.06 | (4.22) | (2.37) | (1.53) |
Capital Expenditures |
(0.01) | — | (0.01) | (0.24) | — | — | — | — | — |
Net Current Asset Value |
171.81 | 94.72 | 10.68 | 20.47 | 38.42 | 9.78 | (4.49) | (2.37) | (1.53) |
EV/EBIT |
— | — | 0.26 | 0.51 | 0.95 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | — | 0.05 | 1.97 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.00 | 0.56 | 2.42 | 0.03 | — | — | — | — | — |
Cash ROIC |
(7.91%) | (9.95%) | (74.70%) | (39.91%) | (18.06%) | (4.76%) | 7.57% | (179.47%) | 13.11% |
Accounts Receivable Turnover |
— | — | 0.00 | 1.65 | 7.01 | 1.12 | 0.00 | 12.36 | 6.31 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | — | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | — | — | — | — | — |
Average Receivables |
— | — | — | 0.08 | 0.44 | 0.62 | — | 0.33 | 0.33 |
Average Payables |
1.05 | 0.79 | 0.90 | 1.12 | 1.41 | 1.36 | 0.98 | 0.65 | 0.65 |
Average Assets |
139.90 | 56.55 | 19.72 | 33.70 | 28.63 | 7.41 | 1.44 | 1.42 | 1.57 |
Average Common Equity |
133.89 | 52.92 | 16.01 | 29.73 | 24.10 | 2.65 | (2.63) | (1.11) | (1.11) |
Columns are period end dates